ArticleMedicine2026
Sarcopenia in systemic sclerosis-associated interstitial lung disease: A cross-sectional radiological and functional assessment.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a significant complication that impairs lung function and increases morbidity. Sarcopenia, characterized by the loss of muscle mass and function, is commonly found in chronic diseases such as systemic sclerosis. This study aimed to evaluate the prevalence of sarcopenia in patients with SSc-ILD and investigate its cross-sectional associations with pulmonary function test parameters, estimated pulmonary artery pressure and quantitative radiological lung involvement. In this cross-sectional study conducted between 2024 and 2025, 40 patients with systemic sclerosis (2013 ACR/EULAR criteria) and high-resolution computed tomography-confirmed interstitial lung disease were evaluated. Patients with overlap myositis, acute infections, severe orthopedic/neurological limitations, and end-stage organ failure were excluded. Sarcopenia was diagnosed based on European Working Group on Sarcopenia in Older People 2 criteria using muscle mass (bioelectrical impedance analysis) and handgrip strength measurements. Pulmonary function tests (FVC, single-breath transfer factor of lung for carbon monoxide), echocardiographic sPAP estimations, and quantitative high-resolution computed tomography lung density analysis were performed. These findings highlight the potential impact of sarcopenia on lung function and the association of sarcopenia with radiological findings in SSc-ILD SSc-ILD. Among the 40 analyzed patients (mean age: 55.8 ± 10.8 years, 85.0% female, mean BMI: 28.7 ± 5.0 kg/m2), sarcopenia was identified in 10 patients (25.0%). Patients with and without sarcopenia were compared to analyze its effects on pulmonary function and radiological findings. Patients with sarcopenia had significantly lower lung diffusion capacity (transfer factor of lung for carbon monoxide) and forced vital capacity % values and significantly higher radiological lung involvement compared to those without sarcopenia (P = .004, P = .023, and P = .035, respectively). Systolic pulmonary artery pressure was also significantly higher in sarcopenic patients (P = .031). Additionally, fat-free mass index, fat-free mass, muscle mass, and handgrip strength were significantly lower in sarcopenic patients (P < .001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.